ISR - IsoRay, Inc.

NYSE American - NYSE American Delayed Price. Currency in USD
0.549398
-0.017602 (-3.10%)
At close: 3:58PM EDT
Stock chart is not supported by your current browser
Previous Close0.567000
Open0.580000
Bid0.000000 x 900
Ask0.000000 x 1100
Day's Range0.541300 - 0.580000
52 Week Range0.360000 - 1.220000
Volume495,400
Avg. Volume1,438,092
Market Cap36.992M
Beta1.42
PE Ratio (TTM)N/A
EPS (TTM)-0.113000
Earnings DateSep 26, 2018 - Oct 1, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est1.55
Trade prices are not sourced from all markets
  • ACCESSWIRE29 days ago

    Free Technical Research on IsoRay and Three More Medical Supplies Equities

    On Friday, July 20, 2018, the NASDAQ Composite, the Dow Jones Industrial Average, and the S&P 500 edged lower at the closing bell. Taking into consideration last Friday's market sentiment, WallStEquities.com assessed the following Medical Instruments & Supplies equities this morning: IsoRay Inc. (NYSE AMER: ISR), STAAR Surgical Co. (NASDAQ: STAA), Conformis Inc. (NASDAQ: CFMS), and Integra LifeSciences Holdings Corp. (NASDAQ: IART).

  • GlobeNewswirelast month

    IsoRay, Inc. Closes $8,250,000 Registered Direct Offering

    IsoRay, Inc. (NYSE American: ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications for the treatment of prostate, brain, lung, head and neck and gynecological cancers, announced today that it closed its previously announced $8,250,000 registered direct offering with several institutional investors (the “Offering”) of 11,000,000 shares of its common stock at a price of $0.75 per share.  Additionally, IsoRay has also issued to the investors unregistered warrants to purchase up to 5,500,000 shares of common stock. The warrants have an exercise price of $0.75 per share of common stock, are exercisable commencing six months following the issuance date, and expire five and one-half years from the issuance date.  IsoRay intends to use the net proceeds from the Offering, estimated at approximately $7,600,000, after deducting the placement agent fees and estimated offering expenses, for working capital and general corporate purposes, with particular focus on marketing the brain applications and Build Blu™ delivery system for real-time prostrate brachytherapy.

  • MarketWatchlast month

    IsoRay's stock plunges on premarket -leading volume after stock offering

    Shares of IsoRay Inc. (isr) plummeted 36% in premarket-leading volume of over 2.5 million shares, after the medical technology company announced a direct offering of common stock, a day after the stock rocketed higher in the wake of regulatory clearance of its treatment of recurrent brain tumors. The company said it reached agreements to sell 11 million shares to institutional investors at 75 cents a share, which was 30% below Monday's closing price of $1.07. The offering would increase shares outstanding by about 20%.

  • ACCESSWIRElast month

    Today's Research Reports on Stocks to Watch: Staffing 360 Solutions and IsoRay

    NEW YORK, NY / ACCESSWIRE / July 10, 2018 / Both Staffing 360 Solutions and IsoRay were two of the biggest winners in Monday’s trading session with gains of about 300% and 143% respectively. The company, which is an innovator in seed brachytherapy and medical radioisotope applications for the treatment of prostate, brain, lung, head and neck and gynecological cancers, said it plans to use the net proceeds from this offering for working capital and general corporate purposes with particular focus on marketing the brain applications and Build-Blu™ delivery system for real-time prostate brachytherapy.

  • IsoRay Stock Jumps 160% on FDA Clearance for Brain Tumor Therapy
    Market Realistlast month

    IsoRay Stock Jumps 160% on FDA Clearance for Brain Tumor Therapy

    Today, IsoRay Inc. (ISR) stock rallied ~160% and closed trading at $1.14, compared to its previous closing price of $0.44. IsoRay’s stock price was triggered by buoyed investor sentiment on the news of the FDA 510(k) clearance for the company’s GammaTile therapy for the treatment of recurrent brain tumors.

  • GlobeNewswirelast month

    IsoRay Announces $8.25 Million Registered Direct Offering

    IsoRay, Inc. (NYSE American: ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications for the treatment of prostate, brain, lung, head and neck and gynecological cancers, today announced that it has entered into definitive agreements with several institutional investors for the purchase in a registered direct offering of 11,000,000 shares of its common stock, at a purchase price of $0.75 per share, for gross proceeds of $8.25 million. Additionally, IsoRay has also agreed to issue to the investors unregistered warrants to purchase up to 5,500,000 shares of common stock. The warrants have an exercise price of $0.75 per share of common stock, will be exercisable commencing six months following the issuance date, and will expire five and one-half years from the issuance date.

  • GlobeNewswirelast month

    IsoRay Announces FDA Clearance of GammaTile™ Therapy for the Treatment of Recurrent Brain Neoplasms

    IsoRay, Inc. (NYSE American: ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications for the treatment of prostate, brain, lung, head and neck and gynecological cancers and GT Medical Technologies, Inc., today announced the receipt of FDA 510(k) regulatory clearance for the brachytherapy technology, known as GammaTile™ Therapy that incorporates proprietary Cesium-131 seeds within customizable collagen-based carriers for the treatment of recurrent brain tumors. IsoRay Medical, Inc., a wholly owned subsidiary of IsoRay, Inc., and GT Medical Technology had previously executed a collaborative development agreement and an exclusive ten-year supply agreement for GammaTile Therapy.  GammaTile leverages Cesium-131’s unique ability to deliver a highly targeted dose of intense radiation treatment while limiting radiation exposure to surrounding tissue.  The Centers for Medicare and Medicaid Services (CMS) has already clarified the coding for GammaTile in the hospital setting by assigning GammaTile Therapy to a new, specific ICD-10-PCS code.  Now that the FDA has issued regulatory clearance for GammaTile, the therapy can be made available in the near future to patients served by hospitals throughout the United States.

  • GlobeNewswire2 months ago

    IsoRay Announces Entry into Employment Agreement with Lori A. Woods as Interim CEO

    Richland, Wash., June 19, 2018 (GLOBE NEWSWIRE) --  – IsoRay, Inc. (NYSE American: ISR) (the “Company”), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications for the treatment of prostate, brain, lung, head and neck and gynecological cancers, is pleased to announce that it has entered into a one-year employment contract with Lori A. Woods, as Interim Chief Executive Officer and as a Director on the Company’s Board of Directors.  Lori Woods was appointed Interim CEO and as a director effective as of June 4, 2018. Chairman of the Board Mick McCormick stated, “The Board and employees have high confidence in Lori Woods that has been built through the years that she has served at IsoRay.

  • GlobeNewswire3 months ago

    IsoRay Announces the Resignation of Chairman and CEO Thomas LaVoy; Industry Veteran Lori Woods Appointed Interim CEO; Mick McCormick Appointed Chairman of the Board

    IsoRay, Inc. (NYSE American: ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications for the treatment of prostate, brain, lung, head and neck and gynecological cancers, today announced that Thomas LaVoy has resigned from his positions as Chairman of the Board and Chief Executive Officer of the Company, effective as of June 4, 2018.  Mr. LaVoy had been a Director of the Company since 2005.  He was appointed Chairman of the Board in January 2016 and took office as Chief Executive Officer of the Company on February 15, 2016.

  • ACCESSWIRE3 months ago

    IsoRay to Present at the 8th Annual LD Micro Invitational

    LOS ANGELES, CA / ACCESSWIRE / May 31, 2018 / IsoRay, Inc. (NYSE American: ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications for the treatment ...

  • GlobeNewswire3 months ago

    IsoRay Announces Signing of Research Funding with Ochsner Clinic Foundation to Support Brain Cancer Treatment Research

    The funding is intended to support a study entitled “Comparison of Minimally Invasive Keyhole Craniotomy and Stereotactic Radiosurgery for the Treatment of New Brain Oligometastases: A Prospective, Open Label Study”.  The study will be led by Dr. Marcus Ware M.D., Ph.D., Medical Director of Neurosurgical Oncology at Ochsner. Dr. Ware is a Harvard Medical School graduate who completed his residency at the University of California, San Francisco, one of the premiere programs in the world in brain tumor surgery and neuro-oncology. At Ochsner, he specializes in the treatment of primary and metastatic brain tumors.

  • When Will IsoRay Inc (NYSEMKT:ISR) Breakeven?
    Simply Wall St.3 months ago

    When Will IsoRay Inc (NYSEMKT:ISR) Breakeven?

    IsoRay Inc’s (AMEX:ISR): IsoRay, Inc., through its subsidiary, IsoRay Medical, Inc., develops, manufactures, and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases inRead More...

  • ACCESSWIRE3 months ago

    IsoRay, Inc. Discusses Competitive Landscape, FDA Clearance for New Product Line and Growth Drivers in New SNNLive Video Interview with StockNewsNow.com

    LOS ANGELES, CA / ACCESSWIRE / May 17, 2018 / StockNewsNow.com , The Official MicroCap News Source™, today published an SNNLive Video Interview with Tom LaVoy, Chairman of the Board & CEO of IsoRay, Inc. ...

  • Want To Invest In IsoRay Inc (NYSEMKT:ISR)? Here’s How It Performed Lately
    Simply Wall St.3 months ago

    Want To Invest In IsoRay Inc (NYSEMKT:ISR)? Here’s How It Performed Lately

    For long term investors, improvement in profitability and outperformance against the industry can be important characteristics in a stock. In this article, I will take a look at IsoRay Inc’sRead More...

  • Associated Press4 months ago

    IsoRay: Fiscal 3Q Earnings Snapshot

    The Richland, Washington-based company said it had a loss of 2 cents per share. The isotope-based medical products maker posted revenue of $1.6 million in the period. In the final minutes of trading on ...

  • ACCESSWIRE4 months ago

    Isoray (ISR) Stock: Circles Back Toward Leadership Position in Treating Prostate Cancer

    Original Source: CNA Finance CORAL SPRINGS, FL / ACCESSWIRE / April 24, 2018 / If an investor pitched me on all of the positive features of IsoRay, Inc. (NYSE American: ISR ) and told me at the end of ...

  • ACCESSWIRE4 months ago

    IsoRay to Present at the Planet MicroCap Showcase 2018 on April 25 in Las Vegas, NV

    RICHLAND, WA / ACCESSWIRE / April 19, 2018 / IsoRay, Inc. (NYSE American: ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications for the treatment ...

  • Associated Press6 months ago

    IsoRay reports 2Q loss

    The Richland, Washington-based company said it had a loss of 3 cents per share. The isotope-based medical products maker posted revenue of $1.5 million in the period. The company's shares closed at 48 ...